Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK inhibitors, have revolutionized the treatment landscape of malignant melanoma, considerably improving patients’ survival. Despite the remarkable improvement in survival, the prevailing unmet needs in first-line unresectable or metastatic malignant melanoma therapies still consolidate around the improvements in efficacy, creating a significant clinical and commercial opportunity for drug developers to exploit with new therapies which can extend patients lives.
- Malignant Melanoma - Unmet Need - Detailed, Expanded Analysis: First-Line Unresectable Or Metastatic Melanoma
Author(s): Michalina Jenkins, MSc, PhD
Michalina Jenkins, M.Sc., Ph.D., is a business insights analyst in the oncology team at Decision Resources Group. She is a specialist in malignant melanoma and has expertise in prostate cancer.
Dr. Jenkins obtained her doctorate in molecular biology of cancer from University of London, where she focused on investigating the impact of phosphoinositide 3-kinases (PI3Ks) signaling on cancer cell biology. Dr. Jenkins holds a M.Sc. in pharmacology from the University of Oxford and a B.Sc. in biotechnology from Oxford Brookes University. Dr. Jenkins worked as a research assistant at Oxford Gene Technology where she was involved in microarray gene expression analysis and R&D projects developing novel gene expression analysis platforms.